| Name | Title | Contact Details |
|---|
Community Partners is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Portland, ME. To find more information about Community Partners, please visit www.cpime.org
Vytra Health Plans is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Launched in 2022 and started from the seeds of LFA Machines and Vivion Inc., Operio Group was conceived from a simple idea: customers do not need machines or ingredients, they need solutions to make products. Operio Group has been set up to invest in companies that directly serve the food, beverage, nutraceutical and pharmaceutical manufacturing industries. Aiming to bring together multidisciplinary teams from different sections of the supply chain in the industries that it serves, Operio Group is able to not just provide products but support people through the consolidated knowledge of their brands.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Kensey Nash Corporation is a medical device company known for product development and technology in the fields of resorbable biomaterials used in a variety of medical procedures and endovascular devices. The Company provides a range of products into